EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Hepatorenal syndrome: Current concepts and future perspectives

Chan-Young Jung, Jai Won Chang

Clinical and Molecular Hepatology · 01.10.2023 · 29 (4) · 891-908

DOI: 10.3350/cmh.2023.0024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2023. Verfasst von Chan-Young Jung und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Hepatorenal Syndrome, Liver Transplantation, Acute Kidney Injury. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatorenal syndrome (HRS), a progressive but potentially reversible deterioration of kidney function, remains a major complication in patients with advanced cirrhosis, often leading to death before liver transplantation (LT). Recent updates in the pathophysiology, definition, and classification of HRS have led to a complete revision of the nomenclature and diagnostic criteria for HRS type 1, which was renamed HRS-acute kidney injury (AKI). HRS is characterized by severe impairment of kidney function due to increased splanchnic blood flow, activation of several vasoconstriction factors, severe vasoconstriction of the renal arteries in the absence of kidney histologic abnormalities, nitric oxide dysfunction, and systemic inflammation. Diagnosis of HRS remains a challenge because of the lack of specific diagnostic biomarkers that accurately distinguishes structural from functional AKI, and mainly involves the differential diagnosis from other forms of AKI, particularly acute tubular necrosis. The optimal treatment of HRS is LT. While awaiting LT, treatment options include vasoconstrictor drugs to counteract splanchnic arterial vasodilation and plasma volume expansion by intravenous albumin infusion. In patients with HRS unresponsive to pharmacological treatment and with conventional indications for kidney replacement therapy (KRT), such as volume overload, uremia, or electrolyte imbalances, KRT may be applied as a bridging therapy to transplantation. Other interventions, such as transjugular intrahepatic portosystemic shunt, and artificial liver support systems have a very limited role in improving outcomes in HRS. Although recently developed novel therapies have potential to improve outcomes of patients with HRS, further studies are warranted to validate the efficacy of these novel agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatorenal SyndromeLiver TransplantationAcute Kidney InjuryHumansLiver CirrhosisVasoconstrictor Agents

Stichwörter der Autor:innen

Acute kidney injuryBiomarkersHepatorenal syndromeLiver cirrhosisTerlipressin

Substanzen

Vasoconstrictor Agents

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Zitieren

APA

Jung, C. Y., & Chang, J. W. (2023). Hepatorenal syndrome: Current concepts and future perspectives. Clinical and Molecular Hepatology, 29(4), 891-908. https://doi.org/10.3350/cmh.2023.0024

Vancouver

Jung CY, Chang JW. Hepatorenal syndrome: Current concepts and future perspectives. Clinical and Molecular Hepatology. 2023;29(4):891-908. doi:10.3350/cmh.2023.0024

BibTeX
@article{Jung2023,
  author = {Jung, Chan-Young and Chang, Jai Won},
  title = {Hepatorenal syndrome: Current concepts and future perspectives},
  journal = {Clinical and Molecular Hepatology},
  year = {2023},
  volume = {29},
  number = {4},
  pages = {891--908},
  doi = {10.3350/cmh.2023.0024}
}
Kostenlos starten →